Top

Published in:

Open Access 01-12-2020 | Chronic Lymphocytic Leukemia | Letter to the editor

Skin testing with bendamustine: what concentration should be used?

Authors: Laura Malinauskiene, Kestutis Cerniauskas, Kotryna Linauskiene, Linas Griguola, Anzelika Chomiciene, Audra Blaziene

Published in: Allergy, Asthma & Clinical Immunology | Issue 1/2020

Abstract

We present a case of the patient, who developed hypersensitivity reaction during the treatment of chronic lymphocytic leukemia. Bendamustine was suspected as a culprit agent. The patient as well as 3 controls underwent skin testing with the concentrations of the bendamustine described in earlier studies. We doubted the testing recommendations as all the controls developed serious local reactions. The clinical meaning of the positive skin test reaction in the patient remained unclear and questioned the safeness of recommended testing concentrations as in certain situations wrong diagnosis could be made or even harm could be done. Future investigations are needed when allergy to bendamustine is suspected.

Leoni LM. Bendamustine: rescue of an effective antineoplastic agent from the mid-twentieth century. Semin Hematol. 2011;48:S4–11.CrossRef

Martin Garcia C, Sierra Pacho M, Moreno Rodilla E, et al. Successful bendamustine desensitization for a delayed-type hypersensitivity reaction. J Investig Allergol Clin Immunol. 2019;29:68–9.CrossRef

Barbarroja-Escudero J, Sanchez-Gonzalez MJ, Antolin-Amerigo D, Rodriguez-Rodriguez M, Alvarez-Mon M. Hypersensitivity reactions and drug fever by bendamustine: a case report of three patients. Allergol Int. 2015;64:109–11. https://doi.org/10.1016/j.alit.2014.08.011.CrossRefPubMed

Brockow K, Garvey LH, Aberer W, et al. Skin test concentrations for systemically administered drugs—an ENDA/EAACI Drug Allergy Interest Group position paper. Allergy. 2013;68:702–12.CrossRef

European medicines agency. Bendamustine hydrochloride. Annex I. Scientific conclusions and grounds for the variation to the terms of the Marketing Authorisation(s). https://www.ema.europa.eu/en/documents/psusa/bendamustine-hydrochloride-cmdh-scientific-conclusions-grounds-variation-amendments-product/00003162/201701_en.pdf. Accessed 1 June 2020.

Title: Skin testing with bendamustine: what concentration should be used?
Authors: Laura Malinauskiene
Kestutis Cerniauskas
Kotryna Linauskiene
Linas Griguola
Anzelika Chomiciene
Audra Blaziene
Publication date: 01-12-2020
Publisher: BioMed Central
Keyword: Chronic Lymphocytic Leukemia
Published in: Allergy, Asthma & Clinical Immunology / Issue 1/2020
Electronic ISSN: 1710-1492
DOI: https://doi.org/10.1186/s13223-020-00469-3

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Skin testing with bendamustine: what concentration should be used?

Abstract

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 1/2020

Patient and physician perceptions of seasonal allergic rhinitis and allergen immunotherapy: a parallel physician patient survey

A single centre retrospective study of systemic reactions to subcutaneous immunotherapy

The effect of electronic monitoring combined with weekly feedback and reminders on adherence to inhaled corticosteroids in infants and younger children with asthma: a randomized controlled trial

Season of birth is associated with increased risk of atopic dermatitis in Japanese infants: a retrospective cohort study

Th17/Treg imbalance is associated with reduced indoleamine 2,3 dioxygenase activity in childhood allergic asthma

The presence of overlapping quality of life symptoms in primary antibody deficiency (PAD) and chronic fatigue syndrome (CFS)